Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group

Leavey, Patrick J.; Mascarenhas, Leo; Marina, Neyssa; Chen, Zhengjia; Krailo, Mark; Miser, James S.; Brown, Ken; Tarbell, Nancy J.; Bernstein, Mark L.; Granowetter, Linda; Gebhardt, Mark C.; Grier, Holcombe E.

doi:10.1002/pbc.21618

Cited by 173 publications

(162 citation statements)

References 11 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Late relapse (≥2 years from the time of original diagnosis), lung-only metastases, local recurrence that can be treated with radical surgery, and intensive chemotherapy are the most favorable prognostic factors, whereas early relapse (<2 years from the time of original diagnosis) with metastases in lungs and/or other sites, recurrence at local and distant sites, elevated LDH level at initial diagnosis, and initial recurrence are considered adverse prognostic factors. [53][54][55][56] In a recent retrospective analysis, site of first relapse and time to first relapse were significant prognostic factors for adult patients with localized Ewing sarcoma. 57 The probability of 5-year postrelapse survival was 50% and 13% for patients with local and distant relapse, respectively.…”

Section: Treating Relapsed/refractory Diseasementioning

confidence: 99%

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Biermann

Chow

Reed

et al. 2017

J Natl Compr Canc Netw

237

187

View full text Add to dashboard Cite

show abstract

Section: Treating Relapsed/refractory Diseasementioning

confidence: 99%

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Biermann

Chow

Reed

et al. 2017

J Natl Compr Canc Netw

237

187

View full text Add to dashboard Cite

show abstract

“…Egger's test (19,20,(22)(23)(24)(25). The funnel plot for this meta-analysis revealed evidence of symmetry, and the P-value from the Egger's test was 0.707 in the OS studies (Fig.…”

Section: Meta-analysismentioning

confidence: 79%

“…1 shows a flow diagram of the selection process for defining the relative studies. Following the process of selection, nine studies met the inclusion criteria and were included in the meta-analysis (17)(18)(19)(20)(21)(22)(23)(24)(25). The major characteristics of the nine eligible publications are shown in Table I.…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Yang

Wang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.A number of studies have investigated the role of serum lactate dehydrogenase (LDH) levels in patients with Ewing's sarcoma, although these have yielded inconsistent and inconclusive results. Therefore, the present study aimed to systematically review the published studies and conduct a meta-analysis to assess its prognostic value more precisely. Cohort studies assessing the prognostic role of LDH levels in patients with Ewing's sarcoma were included. A pooled hazard ratio (HR) with 95% confidence intervals (CIs) of overall survival (OS) or 5-year disease-free survival (DFS) was used to assess the prognostic role of the levels of serum LDH. Nine studies published between 1980 and 2014, with a total of 1,412 patients with Ewing's sarcoma, were included. Six studies, with a total of 644 patients, used OS as the primary endpoint and four studies, with 795 patients, used 5-year DFS. Overall, the pooled HR evaluating high LDH levels was 2.90 (95% CI: 2.09-4.04) for OS and 2.40 (95% CI: 1.93-2.98) for 5-year DFS. This meta-analysis demonstrates that high levels of serum LDH are associated with lower OS and 5-year DFS rates in patients with Ewing's sarcoma. Therefore, serum LDH levels are an effective biomarker of Ewing's sarcoma prognosis.

show abstract

“…Increasing survival continued until some specialists suggested that 'cure' is possible for patients with Ewing's sarcoma (Weston et al, 2004). Third the five year survival rates in recurrent disease is only 13% (Leavey et al, 2008). Therefore appropriate therapy is critical.Our knowledge about Ewing's sarcoma in Iran turns back to only two epidemiologic studies.…”

Section: Discussionmentioning

confidence: 99%

“…Ewing's sarcoma after osteosarcoma is the second most common malignant bone tumor occurring in children and young adults, and accounts for 10-15% of all primary bone tumors (Burchill, 2003;Leavey et al, 2008;Lisa et al, 2013). During the last decades survival of patients with Ewing's sarcoma has been improved significantly (Cangir et al, 1990;Oberlin et al, 2001;Rosito et al, 1999;Ginsberg et al, 2010;Haeusler et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Ewing's Sarcoma in Yazd-Iran

Akhavan

Binesh²,

Shamshiri³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The Ewing's sarcoma family is a group of small round cell tumors which accounts for 10-15% of all primary bone neoplasms. The aim of this study was to evaluate the survival of Ewing's sarcoma patients in our province and to determine of influencing factors. Materials and Methods: All patients with documented Ewing's sarcoma/ primitive neuroectodermal tumor(PNET) family pathology were enrolled in this study during a period of eight years. For all of them local and systemic therapy were carried out. Overall and event free survival and prognostic factors were evaluated. Results: Thirty two patients were enrolled in the study. The median age was 17.5 years. Twenty (65.2%) were male and 9 (28.1%) were aged 14 years or less. Mean disease free survival was 26.8 (95%CI; 13.8-39.9) months and five year disease free survival was 26%. Mean overall survival was 38.7 months (95%CI; 25.9-50.6) and median overall survival was 24 months. Five year overall survival was 25%. From the variables evaluated , only presence of metastatic disease at presentation (p value=0. 028) and complete response (p value =0. 006) had significant relations to overall survival. Conclusions: Survival of Ewing's sarcoma in our province is disappointing. It seems to be mostly due to less effective treatment. Administration of adequate chemotherapy dosage, resection of tumor with negative margins and precise assessment of irradiation volume may prove helpful.

show abstract

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group

Abstract: Background-The prognosis for patients with recurrent Ewing sarcoma is very poor with 5-year survival of 13%.

Cited by 173 publications

References 11 publications

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Survival of Patients with Ewing's Sarcoma in Yazd-Iran

Contact Info

Product

Resources

About